Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial

por Komatsu, Shun-ichiro, Kayukawa, Yoko, Miyazaki, Yoko, Kaneko, Akihisa, Ikegami, Hisashi, Ishiguro, Takahiro, Nakamura, Mikiko, Frings, Werner, Ono, Natsuki, Sakata, Kiyoaki, Fujii, Toshihiko, Kishishita, Shohei, Kitazawa, Takehisa, Endo, Mika, Sano, Yuji
Publicado 2022